14 March 2024   Japanese imaging and electronics firm has acquired non-exclusive licence from ERS Genomics | Technology will be used by Elixirgen Scientific, acquired by Ricoh in 2022.

Latest Features

Big Pharma
The search for clarity goes on as Broad gears up for another set of legal challenges, as Claire Irvine, partner at HGF, explains.
A former Johnson & Johnson IP counsel and a retired judge are among the speakers at Life Sciences IP Due Diligence, on November 29 and 30 in Boston, as LSIPR finds out.
Several recent cases from the US Court of Appeals for the Federal Circuit offer guidance on navigating the §101 legal framework with respect to CRISPR patent claims, as Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.
Stephen Knight was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.
Balancing a company’s duty to shareholders with the public responsibility to provide lifesaving treatments is a constant challenge, as Issi Rozen, chief business officer at the Broad Institute of MIT and Harvard, tells LSIPR.
As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.
Jennifer Doudna was selected in the LSIPR 50 2017 publication for her influence on the life sciences industry. She featured in the business and innovation section, as LSIPR reports.
All features

More News

25 May 2021   The University of California Berkeley has lost a CRISPR patent in Europe in the latest twist in the long-running IP saga over the gene-editing technology.
9 November 2020   The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority. The EPO dealt with three questions in its reasoning.
28 October 2020   Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox.
8 October 2020   French microbiologist Emmanuelle Charpentier and US biochemist Jennifer Doudna have achieved scientific history by jointly winning the Nobel Prize in chemistry for their seminal work on gene-editing technology, CRISPR.
23 September 2020   ERS Genomics, the company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, has appointed Michael Arciero as vice-president of IP and commercial development.
14 September 2020   The Broad Institute and ERS Genomics, a company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, have both claimed victory in the latest round of the CRISPR inventorship battle.
31 July 2020   The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
More news